Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Remedios Garófano"'
Autor:
Javier Naranjo, Francisco Borrego, José Luis Rocha, Mercedes Salgueira, Maria Adoración Martín-Gomez, Cristhian Orellana, Ana Morales, Fernando Vallejo, Pilar Hidalgo, Francisca Rodríguez, Remedios Garófano, Isabel González, Rafael Esteban, Mario Espinosa
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
BackgroundTolvaptan (TV) is the first vasopressin-receptor antagonist approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). No publications report TV experience in real clinical practice during the first year of treatmen
Externí odkaz:
https://doaj.org/article/d05ba1f52546485cbf29ba449c183e8a
Autor:
Javier, Naranjo, Francisco, Borrego, José Luis, Rocha, Mercedes, Salgueira, Maria Adoración, Martín-Gomez, Cristhian, Orellana, Ana, Morales, Fernando, Vallejo, Pilar, Hidalgo, Francisca, Rodríguez, Remedios, Garófano, Isabel, González, Rafael, Esteban, Mario, Espinosa
BackgroundTolvaptan (TV) is the first vasopressin-receptor antagonist approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). No publications report TV experience in real clinical practice during the first year of treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9b50cf9d2c574081b00dae41db99a62
https://hdl.handle.net/10668/20610
https://hdl.handle.net/10668/20610
Autor:
Lozano, Isabel María Jorquera, Navarro, Carlos Federico Gómez, López, Remedios Garofano, Ríos, Elvira Carrión, Molina, Ricardo Fajardo
Publikováno v:
In REC: CardioClinics February 2023 58 Supplement 3:S21-S21
Autor:
Lozano, Isabel María Jorquera, Navarro, Carlos Federico Gómez, López, Remedios Garofano, Ríos, Elvira, Molina, Ricardo Fajardo
Publikováno v:
In REC: CardioClinics February 2023 58 Supplement 3:S21-S21
Autor:
Navarro, Carlos Federico Gómez, Lozano, Isabel María Jorquera, López, Remedios Garofano, Jáimez, Juan Jiménez, Ríos, Elvira Carrión, Molina, Ricardo Fajardo
Publikováno v:
In REC: CardioClinics February 2023 58 Supplement 3:S14-S14
Autor:
Navarro, Carlos Federico Gómez, Lozano, Isabel María Jorquera, López, Remedios Garofano, Jáimez, Juan Jiménez, Ríos, Elvira Carrión, Molina, Ricardo Fajardo
Publikováno v:
In REC: CardioClinics February 2023 58 Supplement 3:S12-S13
Autor:
Adrián Alonso-Núñez, Tania Pérez-Márquez, Marta Alves-Villar, Carlos Fernández-Pereira, Julián Fernández-Martín, Alberto Rivera-Gallego, Cristina Melcón-Crespo, Beatriz San Millán-Tejado, Aurora Ruz-Zafra, Remedios Garofano-López, Rosario Sánchez-Martínez, Elena García-Payá, Manuel López-Mendoza, Ignacio Martín-Suárez, Saida Ortolano
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 11, p 6024 (2024)
Fabry disease is an invalidating multisystemic disorder affecting α-Galactosidase, a rate-limiting hydrolase dedicated to lipid catabolism. Non-metabolized substrates, such as Globotriaosylceramide and its derivatives trigger the direct or indirect
Externí odkaz:
https://doaj.org/article/f6efd209eb834946ab0d655f087e446f
Autor:
Remedios Garófano-López, María Carmen Prados-Soler, Clara Moriana-Domínguez, María Dolores del-Pino y Pino
Publikováno v:
Diálisis y Trasplante. 31:76-78
Calciphylaxis is a serious disease with a poor prognosis due to the limited therapeutic options. Avoiding this complication through prevention is essential. As more specific treatments, the use of thiosulfate, bisphosphonates and hyperbaric chamber c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdd7a0f4887b6c5a4293144ee4584184
https://doi.org/10.1016/j.dialis.2010.05.001
https://doi.org/10.1016/j.dialis.2010.05.001